Nurix Therapeutics Robust Collaboration Agreement Penned with Roche for Bexdeg, Directed Across Breadth of BTK-Driven Diseases

Research evidence excerpt

Nurix Therapeutics Robust Collaboration Agreement Penned with Roche for Bexdeg, Directed Across Breadth of BTK-Driven Diseases

J P M O R G A N North America Equity Research

08 June 2026

Nurix Therapeutics

Robust Collaboration Agreement Penned with Roche Overweight

for Bexdeg, Directed Across Breadth of BTK-Driven NRIX, NRIX US

Diseases Price (05 Jun 26):$14.64

SMid Biotechnology

Tessa T Romero AC

(1-212) 622-4484

tessa.t.romero@jpmchase.com

Caroline Pocher

(1-212) 622-8204

caroline.pocher@jpmchase.com

Nurix announced this morning that it has entered into a global collaboration

Mariam Waggeh

agreement with Roche to develop and commercialize bexobrutideg (bexdeg) across

(1-212) 622-1711

oncology, immunology, and neurology. Outside of the previously disclosed phase 2 mariam.waggeh@jpmchase.com

and phase 3 trials in chronic lymphocytic leukemia (CLL), the collaboration plans to J.P. Morgan Securities LLC

pursue multiple label-enabling studies across malignant hematology indications

(monotherapy and in combination regimens) and to expand development in immune-

mediated diseases, including phase 2 trials in multiple sclerosis (MS) and chronic *Roche is covered by J.P. Morgan

spontaneous urticaria (CSU). In its press release, Roche noted that available data Securities plc European Pharmaceuticals

suggests that the asset has the potential to become a best-in-class treatment option with & Biotechnology analyst, Richard Vosser

higher efficacy and more favorable tolerability than established therapies; further,

Roche indicated excitement around exploring combination regimens utilizing

selected agents from its portfolio of successful B-cell malignancy drugs. Overall, we

believe this partnership meaningfully enhances the bexdeg development program and